文献速递炎症性肠病

溃疡性结肠炎中乌司奴单抗延迟应答者基线炎症负荷更高但结局与早期应答者相似

Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-06-29

本研究为UNIFI临床试验的事后分析,纳入642例乌司奴单抗治疗的溃疡性结肠炎患者,比较第8周早期应答者(321例,50%)、第16周延迟应答者(115例,17.9%)和无应答者(205例,32.1%)的1年结局。结果显示早期与延迟应答者1年临床缓解率无显著差异(41.1% vs 34.8%,P=0.233),但延迟应答者基线Mayo内镜病变更严重且C反应蛋白异常比例更高,延迟应答者至第16周C反应蛋白和粪钙卫蛋白显著下降。

要点

  • 乌司奴单抗治疗溃疡性结肠炎中,早期与延迟应答者1年临床缓解率无显著差异。
  • 延迟应答者较早期应答者基线内镜病变更严重、C反应蛋白异常比例更高。
  • 延迟应答者至第16周C反应蛋白和粪钙卫蛋白显著下降,有助于与无应答者区分。

核心结论

  • 与乌司奴单抗早期应答者相比,延迟应答者基线炎症负荷更高,但早期与延迟应答者1年结局相似。
  • 延迟应答者中观察到的生物标志物下降有助于将其与无应答者区分。

研究设计与样本

  • 本研究为UNIFI临床试验患者水平数据的事后分析。
  • 共纳入642例乌司奴单抗治疗的溃疡性结肠炎患者,其中早期应答者321例(50%)、延迟应答者115例(17.9%)、无应答者205例(32.1%)。
  • 早期应答定义为第8周临床应答(总Mayo评分较基线下降≥30%且≥3分,同时直肠出血亚评分下降≥1分或直肠出血亚评分≤1分);延迟应答定义为第8周无应答但第16周应答。
  • 主要结局为1年临床缓解,定义为总Mayo评分≤2分且无亚评分>1分。

主要发现

  • 早期与延迟应答者1年临床缓解率无显著差异:早期应答者132/321例(41.1%)vs 延迟应答者40/115例(34.8%),P=0.233。
  • 无论诱导剂量如何,其他评估结局在早期与延迟应答者间均无差异。
  • 延迟应答者较早期应答者基线Mayo内镜病变更严重:88/115例(76.5%)vs 206/321例(64.2%),P=0.015。
  • 延迟应答者较早期应答者基线C反应蛋白>3 mg/L比例更高:83/115例(72.2%)vs 183/321例(57%),P=0.004。
  • 与无应答者相比,延迟应答者至第16周C反应蛋白水平显著下降(F值[自由度,均方] [4, 844],P<0.0001),粪钙卫蛋白水平显著下降(F[4, 818],P<0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Differences in 1-year outcomes among early compared with delayed responders to vedolizumab have been shown in ulcerative colitis. However, it is unclear whether similar differences exist with ustekinumab, and what factors differentiate delayed responders from nonresponders. METHODS: This study was a post hoc analysis of patient-level data from the UNIFI clinical trial. Ustekinumab-treated patients with clinical response, defined as a reduction in total Mayo score of 30% or more and 3 or more points from baseline with a reduction in their rectal bleeding subscore of 1 or more or a rectal bleeding subscore of 1 or less, at week 8 were deemed early responders and their outcomes were compared with delayed responders (week 8 nonresponders who subsequently responded at week 16). The primary outcome assessed was 1-year clinical remission, defined as a total Mayo score of 2 or less and no subscore greater than 1. RESULTS: We included 642 ustekinumab-treated patients, including 321 (50%) early responders, 115 (17.9%) delayed responders, and 205 (32.1%) nonresponders. No differences were observed for 1-year clinical remission among early vs delayed responders (132 of 321 [41.1%] vs 40 of 115 [34.8%]; P = .233), or for other outcomes assessed regardless of induction dose. Compared with early responders, delayed responders had more severe baseline Mayo endoscopic disease (88 of 115 [76.5%] vs 206 of 321 [64.2%]; P = .015) and abnormal baseline C-reactive protein level greater than 3 mg/L (83 of 115 [72.2%] vs 183 of 321 [57%]; P = .004). Compared with nonresponders, delayed responders had a significant decrease in C-reactive protein level (F-value [degrees of freedom, mean squares] [4, 844]; P < .0001) and fecal calprotectin level (F[4, 818]; P < .0001) through week 16. CONCLUSIONS: Compared with early ustekinumab responders, delayed responders had a greater inflammatory burden at baseline. Early and delayed responders had similar 1-year outcomes. Biomarker decline observed in delayed responders can help differentiate them from nonresponders.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wong ECL, Dulai PS, Marshall JK, et al. Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders. Clin Gastroenterol Hepatol. 2023. PMID: 37391059. doi:10.1016/j.cgh.2023.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。